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Abstract 
This experiment aimed to establish a model for long and/or short-term ethanol-
withdrawal induced motor deficits and thermal sensitivity in mice. Additionally, the 
effects of ketamine on these phenomena were evaluated. Human studies of alcoholics 
have documented, along with behavioral depression, deficiencies in gait and balance, as 
well as an increase in pain sensitivity, immediately following abstinence, and in some 
cases, lasting many years. Ketamine, an NMDA antagonist, has been shown alleviate 
behavioral depression in both animal and human models, but its physiological 
mechanisms are still being evaluated. Ethanol dependence was induced using chronic 
intermittent alcohol vapor exposure. Low-dose ketamine was injected immediately 
following the 8-day ethanol vapor protocol. Animals were then tested for motor 
coordination via an accelerating rotarod (ARR), and for thermal nociception via the 
radiant heat tail-flick test. Tests were run at 6 hours, 24 hours, then each day for two 
weeks post-withdrawal. Data show a significant, late-emerging effect of ethanol on ARR 
scores, establishing a novel model for long-term ethanol withdrawal-induced motor 
coordination deficiencies in mice. Additionally, no effects of ketamine were observed. 
Finally, No effects of either ethanol or ketamine were seen in the tail-flick assay.  
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Introduction  
Ethanol Withdrawal Syndrome: An Overview 
Alcoholism, otherwise known as alcohol dependence, is a disorder affecting 
millions of people every day in the US and beyond. The National Institute of Alcohol 
Abuse and Alcoholism (NIAAA) estimates 17 million Americans have an alcohol use 
disorder, including alcoholism and other harmful drinking, and sights alcohol use as the 
leading cause of death and disability globally in persons ages 15-49 (NIAAA, 2014). 
Unfortunately, complications related to alcoholism do not cease when a person gives up 
drinking and becomes abstinent from alcohol. Most are aware of the symptoms that can 
arise during the acute stages of ethanol withdrawal, known as alcohol withdrawal 
syndrome, which include tremors, agitation, autonomic hyperactivity, delirium, seizures, 
gait and balance deficiencies, and increased pain sensitivity (hyperalgesia) (Soto et al., 
1985; Jochum et al., 2010; Heilig et al., 2010; Fein et al., 2013; WebMD, 2014).  Such 
symptoms usually resolve within a few days of abstinence. In the weeks to follow, 
anxiety, depression, sleep and circadian rhythm disruption, and continuing motor 
deficiencies often occur (Soto et al., 1985; Soto et al., 1989; Heilig et al., 2010; Fein et 
al., 2013). In some cases, protracted withdrawal symptoms can be observed for months, 
or even years, after a person stops consuming alcohol, including long-term depression 
and anxiety, sleep disturbances, stress-induced craving and relapse, and persistent gait 
and balance disruption (Soto et al., 1985; Soto et al., 1989; Martinotti, 2008; Heilig et al., 
2010; Fein et al., 2013). These symptoms contribute to a condition known as post-acute-
withdrawal syndrome, or PAWS (Addictions and Recovery, 2014). The incidence of 
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post-acute-withdrawal syndrome is a subject of contention, as an unknown number of 
individuals may experience this condition without seeking medical attention. Based on 
various studies conducted in the later half of the twentieth century, PAWS can last 
anywhere from a few months up to 10 years or more, though in all cases symptoms 
tended to become less severe over time (Soto et al., 1985).  
Causes of PAWS can be attributed both to chemical and psychocognitive 
mechanisms (Rimondini et al., 2008). The acute behavioral effects of alcohol 
consumption result in part from the activation of GABAA receptors in a few key areas of 
the brain, including the amygdala (related to anxiety relief), hippocampus (cognitive 
effects), cerebellum (balance deficits), and preoptic area (sleep effects) (Sanna et al., 
2003; Clapp et al., 2008). Repeated long-term exposure to alcohol, as seen in alcoholics, 
produces a tolerance to the behavioral effects due to decreased responsiveness in GABAA 
receptors as a result down regulation of the genetic transcription of specific GABAA 
subunits. During withdrawal, the central nervous system enters a state of 
hyperexcitability as a result of these adaptive changes in the balance of excitatory and 
inhibitory neurotransmission, which has been implicated in relation to the symptoms of 
alcohol withdrawal.  Thus, the pharmacological management of acute withdrawal 
involves the use of drugs that counteract this hyperexcitability, such as benzodiazepines, 
and more recently, acamprosate (Clapp et al., 2008). The time frame for which GABAA 
receptor function returns to normal, baseline levels post-withdrawal is widely variable 
between patients, and may be related to why some individuals develop PAWS and others 
do not (Sanna et al., 2003).   
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The upregulation of glutamate release, in many of the same key brain areas as we 
see GABA affected, is a second important factor in alcohol dependence and long-term 
withdrawal, and thus should be considered in relation to PAWS. Acute exposure to 
ethanol has been found to inhibit glutamatergic transmission in the hippocampus, 
cerebellum, cerebral cortex, and amygdala, contributing to the anxiolitic, sedative, and 
intoxifying effects of alcohol (Clapp et al., 2008). In the presense of chronic alcohol 
exposure, adaptive neural mechanisms compensate for the glutamatergic depression, 
leading to an eventual increase in glutamate release. Here we see interplay between 
GABA and glutamate systems, in that heightened activity in glutamate interneurons 
further inhibit action from GABA neurons (Clapp et al., 2008). Upon removal of alcohol 
following chronic exposure, the brain enters a hyperglutamatergic state, contributing to 
symptoms of withdrawal including anxiety and agitation, and thus posing risk for relapse 
(Clapp et al., 2008).  
Other studies postulate that up-regulation of corticotrophin releasing hormone 
(CRH), both within the hypothalamic-pituitary-adrenal (HPA) axis and the amygdala, 
may play a role in the development of PAWS, as heightened CRH levels are observed in 
these systems during both acute and protracted withdrawal (Clapp et al., 2008; Heilig et 
al., 2010). Whether this chemical imbalance is the cause or a byproduct is a point of 
contention, as the stress, anxiety, and depression associated with PAWS may bring about 
the rise in CRH. Additionally, the role of mesolimbic dopamine reward pathways has 
been implicated in underlying the symptomology of both alcohol withdrawal syndrome 
and PAWS through motivational learning and reward models (Heilig et al., 2010).  
 4 
Motor Deficits Following Ethanol Withdrawal 
In human studies, disturbances in gait and balance are exceptionally well 
documented in abstinent alcoholics. In fact, impairments in these areas are considered to 
be among the most consistent and noticeable results of chronic alcoholism (Smith et al., 
2011). Research has shown that the initial disturbances in motor coordination 
experienced by abstinent alcoholics does improve with time, but the length of time 
associated with recovery is still a matter of debate (Smith et al., 2011; Fein et al., 2012). 
Studies suggest that little improvement in gait and balance deficits occurs over the first 
year after withdrawal; return to normal balance begins during year 2 of abstinence and 
progresses slowly for a period of up 10 years. Causes of motor impairment following 
alcoholism are generally attributed to cerebral damage caused by frequent exposure to 
high concentrations of ethanol. Notable damage has been observed in the cerebellum, 
hippocampus, and corpus callosum following alcoholism, all areas related to movement 
and coordination (Fein et al., 2012).  
Animal research in this area is far more limited. Studies have established the 
accelerating rotarod (AAR) as effective tool for testing motor coordination in mice 
(Philibin et al., 2011). While the AAR has been used extensively to measure intoxication 
in animals, its use to test persistent motor deficits following alcohol withdrawal has only 
been demonstrated in a few studies. An AAR consists of a shaft upon which a mouse is 
placed and required to balance. The shaft then rotates at progressively increasing speeds, 
requiring a higher degree of coordination to prevent falling. The height of the rod is 
enough to induce a desire not to fall, but not enough to cause injury when the fall occurs 
(Figure 1). Philibin et al. (2011) treated mice with chronic intermittent ethanol vapor 
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exposure to induce alcohol dependence, and found significant deficits in ARR scores 
compared to air exposed mice. However, this study only tested CIE withdrawing mice at 
8-hours post-withdrawal. An additional experiment conducted by Philibin et al. (2012) 
exposed animals to constant ethanol vapor, and performed ARR testing for 1 week 
following. The results of this study found ethanol effects to last between 1-4 days. No 
work has previously been conducted to establish the long-term (i.e. longer than 1 week) 
effects of CIE exposure on motor coordination in mice.    
http://ppw.kuleuven.be/ 
Figure 1: Accelerating Rotarod 
Pain Sensitivity Following Ethanol Withdrawal 
There is a somewhat more prevalent literature on pain sensitivity in abstinent 
alcoholic animals, but the research on this area in humans is sparse. However, studies 
have indeed found that humans undergoing withdrawal from alcohol dependence 
experience an increase in heat pain sensitivity (thermal nociception), though the length of 
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time that this effect persists was not concluded (Jochum et al., 2009). This is consistent 
with the animal research showing a decreased latency in radiant heat tail-flick tests in 
withdrawing alcohol-dependent rats (Gatch et al., 1999; Gatch et al., 2006). Radiant heat 
tail-flick tests function by placing the tail of an animal on a heated surface that steadily 
increases in temperature; the amount of heat an animal can withstand before moving its 
tail provides a measure of its pain sensitivity (Figure 2). Therefore, a shorter amount of 
time before a tail-flick occurs in abstinent alcoholic mice suggests an increase in pain 
sensitivity. Gatch et al., 1999, administered alcohol via liquid diet for a period of 10 days, 
and tested thermal nociception over the next 36 hours, finding significant hyperalgesia 
for only the first 12 hours. However, similarly to the animal studies of balance and gait 
impairment, these tests did not look at long-term effects. Furthermore, no studies to date 
have evaluated thermal nociception in animals following chronic intermittent ethanol 
exposure.  
 
http://ja.brc.riken.jp/ 
Figure 2: Radiant Heat Tail-flick Test 
Prior Work  
 The chronobiology lab of Dr. Alan M. Rosenwasser has conducted extensive 
research on models of alcoholism in animals. While many past studies have focused on 
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circadian rhythm disruptions revolving around alcohol consumption and withdrawal, 
lately the lab has begun explorations into alcohol withdrawal syndrome, post-acute 
withdrawal syndrome, and investigating various pharmaceuticals to treat these 
conditions. Logan et al. (2010, 2011) employed a chronic intermittent ethanol (CIE) 
exposure protocol previously developed by Becker et al. (1997) to induce alcohol 
dependence in mice, as an analog for human alcoholism. This protocol involved the use 
of ethanol vapor chambers, with alternating periods of ethanol exposure and plain air. 
Following treatment, Logan observed a significant reduction in wheel running activity in 
ethanol-exposed mice, lasting approximately 1 week before returning to baseline levels. 
These two papers found that B6 mice show a 1-week deficit but C3H mice show an effect 
that lasts at least 30 days. Wheel running is a pleasure seeking activity for caged mice 
and a reduction in wheel running would suggest a reduction in pleasure seeking 
behaviors, known as anhedonia (Brene et al., 2007). Anhedonia is a commonly cited 
symptom of human depression, such as that seen in withdrawing abstinent alcoholics, and 
thus would suggest the mice exhibiting this symptom are experiencing a state analogous 
to human depression.  
 Following the success of the Logan et al. (2010, 2011) studies, the Rosenwasser 
lab began research on how antidepressant pharmaceuticals would impact wheel-running 
activity in CIE withdrawing animals. Desipramine, a tricyclic antidepressant prescribed 
in humans, was the first drug to be evaluated. Unfortunately, the results of this study were 
disappointing, in that chronic desipramine completely failed to reverse withdrawal-
induced hypolocomotion (unpublished data). The present study evaluated the effects of a 
different drug, ketamine, on CIE withdrawing animals. As described below, ketamine is 
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currently under intense experimental investigation as a possible rapid-acting 
antidepressant drug. A study conducted in parallel by Edwards et al., 2014, examined the 
effects of ketamine on wheel running activity, while this study diverged in a direction not 
previously taken by the Rosenwasser lab, looking at motor coordination and nociception 
following CIE exposure.  
Potential Therapeutic Effects of Ketamine 
Ketamine, an NMDA receptor antagonist, has been used as an intramuscular and 
intravenous anesthetic in both human and veterinary medicine since the 1970s (Salvadore 
& Singh, 2013). Beginning in the early 2000s with a study by Berman et al., 2000, the 
possible role of ketamine in the treatment of major depression began to be explored, with 
a number of other studies being conducted from that time to present day. Research has 
shown that a single, sub-anesthetic does of ketamine can produce rapid antidepressant 
effects in treatment-resistant depressed patients within 2 hours, lasting for about a week 
(Burman et al., 2000). While the safety and mechanisms by which ketamine produces 
these dramatic antidepressant effects are not yet completely understood, researchers 
remain hopeful for the future use of ketamine to treat major depression.  
At anesthetic doses, ketamine blocks the function of NMDA glutamate receptors 
(Salvadore & Singh, 2013). However, at low, sub-anesthetic doses, we see a very 
different phenomenon occur, in that ketamine dramatically increases glutamate release 
for an acute period (around 2 hours) (Salvadore & Singh, 2013). One hypothesis suggests 
that low-dose ketamine may block NMDA receptors on GABAergic interneurons, thus 
disinhibiting glutamatergic pyramidal cells and increasing glutamate release in the 
prefrontal cortex (Duman et al., 2012). It should also be noted that the response of AMPA 
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receptors to the upsurge of synaptic glutamate release is imperative to the antidepressant 
effects of ketamine, as AMPA antagonists administered before ketamine injections 
completely abolish these effects (Salvadore & Singh, 2013). The role of synaptic 
potentiation has also been implicated in ketamine’s antidepressant properties, as acute 
increased translation of brain-derived neurotrophic factor (BDNF), an essential 
component in forming neural connections, has been observed in the hippocampus shortly 
following ketamine administration (Salvadore & Singh, 2013). This may be a crucial 
factor in ketamine’s mechanism of action as decreased synaptic connectivity in various 
regions of the brain, including the hippocampus, can be observed in patients with major 
depression, likely due to heightened levels of CRH (Zhou, 2013).  
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The Present Study 
The aims of this study are:  
1. To establish a long-term animal model of motor impairment following CIE 
withdrawal. 
2. To establish an animal model for heightened pain sensitivity following CIE 
withdrawal.  
3. To evaluate the effects of ketamine on motor coordination and pain sensitivity in 
CIE withdrawing mice, in order to hypothesize how these symptoms may be 
influenced if ketamine were used to treat PAWS-related depression in humans.  
Materials and Methods 
Subjects and Apparatus 
Upon arrival in the laboratory, 6 to 8 week old male C3H mice (Jackson 
Laboratories, Bar Harbor, ME), were weighed and housed in groups of 5 in cages without 
running wheels (Figure 3). Food (Prolab RMH 3000; LabDiet, St. Louis, MO) placed on 
the bottom of the cage, and tap water through long drinking tubes, were freely available 
throughout the process.  
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Figure 3: Cage Set-up 
Treatments  
Animals underwent chronic intermittent ethanol exposure (CIE) while group-
housed in standard mouse cages (Figure 4). CIE exposure protocol was based on the 
work of Logan et al., University of Maine. CIE animals (n=20) were administered a 
priming injection containing 1.6 g ⁄ kg ethanol and 68.1 mg⁄ kg pyrazole HCl to stabilize 
blood ethanol concentration and inhibit ethanol metabolism. Pyrazole was dissolved in 
20% ethanol solution and injected subcutaneously in a volume of 10mg/kg of body 
weight, while control animals (n=20) were given a comparable dose of pyrazole in 0.9% 
saline solution at the same volume. All animals were weighed prior to and following the 
8-day CIE cycle to ensure appropriate injection volumes, and to monitor possible CIE-
induced changes in body weight. Air and ethanol vapor were delivered to the exposure 
chambers at a rate of 10 to 12 l ⁄ min, allowing for satisfactory airflow to meet the 
animals’ breathing requirements. Ethanol was vaporized using a pressurized pump to 
push air through a porous diffusing stone submerged in a 1.0-l bottle filled with 95% 
ethanol. To ensure ethanol vapor concentrations were within an appropriate range (10 to 
12 mg ⁄ l) and stable across treatment days, 5.0-ml air samples were extracted from the 
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ethanol chambers using a 60-ml syringe and mixed with 55.0 ml of ambient air. The 
diluted sample was injected into a breathalyzer (Lifeloc FC-10; Wheat Ridge, CO) and 
the resultant readings were compared to a standardized calibration curve of known 
ethanol concentration to determine chamber ethanol concentration. Lights were kept on 
an LD 12/12 cycle, with 16 hours of vapor exposure followed by 8 hours of plain air 
daily. Ethanol vapor was initiated 2 hours before the dark phase of the cycle, with pyrazol 
HCL and saline injections occurring shortly before vapor exposure each day; vapor was 
terminated 2 hours into the light portion of the cycle. This allowed the maximum vapor 
exposure to occur during the peak activity periods of the animals. Vapor chamber 
treatments lasted 8 days. The entire experiment was conducted twice due to space 
limitations, with 20 animals in each round, for a total of 40 animals with 10 in each 
treatment condition.  
 
Figure 4: Ethanol Vapor Chambers 
Measurement of Blood Ethanol Content 
BECs were measured in experimental animals at the termination of the 8-day CIE 
exposure. Briefly, each mouse was removed from the cage and gently placed in a plastic 
restraining tube, and a small (approximately 10 ll) blood sample was collected from the 
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tip of the tail, then centrifuged for 2 minutes to separate plasma from serum. BECs were 
determined from 5 ll plasma samples using an AM-1 alcohol analyzer (Analox 
Instruments, Lunenburg,MA). 
Ketamine Injections  
Immediately following removal from the vapor chambers at the end of the 8-day 
CIE protocol, test animals (n=20, 10 from ethanol exposed treatment and 10 from air 
exposed controls) were administered a single, sub-anesthetic injection of ketamine 
(10mg/kg). Following injections, animals were returned to their cages for 6 hours before 
testing began.  
Accelerating Rotarod Test 
An Accelerating Rotarod was used to test balance and motor coordination in CIE-
withdrawn animals. ARR protocol was based on the work of Philbin et al. (2012). 3 
animals at a time were placed on the rod in individual compartments, at a height in which 
falling would not cause physical harm, but still stimulate falling avoidance behavior. 
Once all animals were in position, the motor was turned on and accelerated from 0rmp at 
a constant rate of 20rpm/min. Sensors recorded the time at which each animal fell from 
the rod. Once all had fallen, the motor was reset animals were given 1 minute before 
repeating the test. Each animal was subjected to 3 tests in a row per testing period. ARR 
Testing was conducted at 6hr post-withdrawal, daily for 1 week, then weekly for 1 
month.  
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Tail-flick Assay  
A Tail-Flick Analgesia Meter (Columbus Instruments, Columbus, OH, USA) was 
used to test post-withdrawal thermal nociception in the animals. The tail-flick assay 
procedure used was based on the work of Gatch et al. (1999). Mice were placed in clear 
plastic restrainers, with their tails extending through a notch in the device, and tested 
individually. Tails were laid across an adapter block with movement sensors, and the a 
light beam set at a nominal intensity level of 10 was projected on a point approximately 
half way down the tail. A 0-60 second timer began as soon as the light beam shutter was 
opened, and stopped when tail movement was registered by the sensors. Each animal was 
given 1 minute before repeating the measure, and were tested twice per testing period. 
Tail-flick assays were conducted at 6hr post-withdrawal, then daily for 1 week.  
Ethical Considerations 
This experiment was approved by the University of Maine Institutional Care and 
Animal Use Committee.  
Data Analysis  
Both accelerating rotarod and tail-flick test scores were first analyzed using a 
three -factor analysis of variance (ANOVA) with “ethanol vs. air” and “ketamine vs. 
saline” as between-groups factors and time-blocks as a repeated-measures factor.  This 
approach allowed us to detect possible main effects of ethanol exposure, ketamine 
treatment, and time-blocks, as well as possible ethanol-by-ketamine-by-time interactions.  
This analysis was followed by two-factor (ethanol, ketamine) ANOVA for specific time 
blocks and finally by standard t-tests for pairwise comparisons.  
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Results  
Accelerating Rotarod 
Mean accelerating rotarod scores fell between 25-50 seconds for the initial 6 hour 
post-withdrawal test session, and then appeared to gradually increase over the next month 
(Figure 1), probably indicative of a practice effect in this task. Not surprisingly, then, the 
overall ANOVA detected a significant main effect of time-blocks (F(10,340) = 23.59, p < 
0.001).  In addition, there was a significant main effect of ethanol, in that ethanol-
exposed animals showed reduced time on the rotarod across time-blocks relative to air-
exposed animals (F(1,340) = 7.51, p = 0.01).  There was no main effect of ketamine, nor 
any interactions detected.  Follow-up analyses revealed significant effects of ethanol at 3, 
4, 6 and 7 days post-withdrawal, but no ketamine effect at any time-point.  Together, 
these results suggest a late-emerging effect of ethanol withdrawal on motor coordination 
that emerges a couple of days following withdrawal and lasts about a week. 
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Figure 5. Mean (± standard error of the mean) ARR scores in seconds at time points between 6 hours 
and 4 weeks post-withdrawal across all treatment groups. Asterisks (*) denote a significant 
difference (P <  .05) between control (Air) and treatment groups on ARR performance.  
Tail-Flick Assay 
While the ethanol exposed group appeared to show reduced tail flick latency not 
present in the ethanol-ketamine exposed group at 6 hours post-withdrawal, this effect was 
not significant. Scores did not show any differences between 6 hours and 5 days (Figure 
2). Day 6 revealed a significant (P < .05) difference between the ethanol exposed group 
and all other groups, suggesting a potential late emerging effect of ethanol corrected by 
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ketamine. Tail flick latency did not appear to change within groups between testing 
periods.  
 
Figure 6. Mean (± standard error of the mean) tail-flick scores in seconds at time points between 6 
hours and 1 week post-withdrawal across all treatment groups. Asterisks (*) denote a significant 
difference (P <  .05) between control (Air) and treatment groups on tail-flick performance.  
Discussion  
Motor Coordination 
 These results suggest late-emerging motor deficits in CIE exposed mice beginning 
at day 4 of withdrawal and ending after 1 week post-withdrawal. This effect differs from 
that found previously by Philibin et al., 2012, which showed effects of ethanol at 8 hours 
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post-withdrawal but did not continue testing at later time points. It should be noted that in 
the first round of the present study, impairment was present both in the first 24 hours of 
testing, then again appeared at a late emerging time point, while in the second round, the 
immediate impairment was not apparent. This would suggest that CIE vapor exposure 
protocol produces long-lasting motor deficits in animals, similar to those seen in human 
abstinent alcoholics. The establishment of this animal model for motor deficits following 
alcohol withdrawal opens the door for future research on treatment for this salient 
condition. Mechanisms for this phenomenon may revolved around ethanol-induced 
damage to motor centers in the brain, and/or hippocampal GABAA receptor subunit 
abnormalities, as seen in human alcoholics, though direct neurobiological investigation 
would be needed to verify this hypothesis.  
 In the first round of this study, ketamine appeared to produce and/or exacerbate 
motor coordination deficits for the first 24 hours after administration, yet when combine 
with the results of the second study, this effect was no longer apparent. Thus, we may 
conclude that while ketamine does not reverse motor impairment, it does not worsen it. 
This is applicable to the use of ketamine to treat PAWS-related depression, as motor 
deficits would be an unpleasant side effect.  
Pain Sensitivity 
Contrary to previous research, the present study failed to find an effect of ethanol 
withdrawal on thermal nociception in mice. The first trial of this study saw a significant 
difference between ethanol-exposed animals and air exposed animals at the 6 hour time 
point that was reversed by ketamine, but when combined with data from the second 
round, this effect was no longer significant. There is no conclusive explanation for the 
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appearance of a significant difference between ethanol exposed and air exposed animals 
on day 6 post withdrawal; further research is needed to investigate this finding. Again, 
there was no significant effect of ketamine on pain sensitivity. While this does not imply 
possible treatment options for PAWS patients experiencing analgesia, we do not see 
reason to believe ketamine treatment to adversely affect this symptom.  
Future Directions  
 This study has produced promising implications for the future of research on 
treatment for alcoholism, yet there are still questions to be answered and further work to 
be done. Firstly, to conclude more certainly that ketamine does not have effects on the 
processes in question, a dose-response curve for ketamine in mice should be generated. 
While the dose used was sub-anesthetic and thus theoretically comparable to the doses 
used in humans, the potential for differing responses in mice is likely. Second, as results 
obtained between the two trials of the study were varied, more trials should be conducted. 
The statistical analysis assumes that both trials were identical when in reality 
uncontrolled factors may have been at play, for example the time of year, atmosphere, 
mice (assumed to be clones, but in reality phenotypic variations exist), and individuals 
conducting testing. More trials would increase the number of subjects and thus the power 
of the study, minimizing the effects of random variables. Finally, recent studies have 
suggested that multiple doses of ketamine may provide longer lasting symptom relief 
from major depression (Murrough et al., 2013). Thus, examining the effects of repeated 
doses on motor coordination and pain sensitivity in CIE withdrawing mice may be 
beneficial to understanding the side effects of such treatments.  
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